✦ LIBER ✦

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

✍ Scribed by Ralph Boccia, Steven Grunberg, Edwin Franco-Gonzales…

Book ID: 120913108
Publisher: Springer-Verlag
Year: 2013
Tongue: English
Weight: 324 KB
Volume: 21
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-012-1691-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness of palonosetron for preven

Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer

✍ Murakami, Michiyasu; Hashimoto, Hiroki; Yamaguchi, Kyohei; Yamaguchi, Ikuko; Sen 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 180 KB

PCN22 COST-EFFECTIVENESS OF PALONOSETRON

PCN22 COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY

✍ Rely, K; Pierre, KA; Salinas, EG 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

A phase III open-label study to assess s

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

✍ Kenjiro Aogi, Hiroshi Sakai, Hirohisa Yoshizawa, Norikazu Masuda, Nobuyuki Katak 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 227 KB

Palonosetron in combination with 1-day v

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

✍ Luigi Celio; Sergio Frustaci; Angela Denaro; Angela Buonadonna; Antonio Ardizzoi 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 185 KB

The efficacy of oral ondansetron and dex

The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy – a retrospective audit

✍ W.L. NG; S.A. DELLA-FIORENTINA 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

Improved prevention of moderately emetog

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist : Results of a Phase III, single-dose trial versus dolasetron

✍ Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Haj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Background: Palonosetron, a highly selective and potent 5-ht(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy in phase ii trials in preventing chemotherapy-induced nausea and vomiting (cinv) resulting from